SCHEDULE: Stonepine Capital Discloses 5.6% Stake in CNS Pharma

Stonepine Capital Management and its affiliates have reported a 5.6% beneficial ownership stake in CNS Pharmaceuticals, Inc. as of October 29, 2025.

Summary

• Stonepine Capital Management, LLC, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico jointly reported beneficial ownership of CNS Pharmaceuticals, Inc. Common Stock.
• The reporting persons collectively beneficially own 32,220 shares of CNS Pharmaceuticals, Inc. Common Stock.
• This ownership represents 5.6% of the outstanding Common Stock of CNS Pharmaceuticals, Inc.
• The percentage is calculated based on 574,580 shares of Common Stock outstanding as of August 14, 2025, as reported in the Issuer's Form 10-Q for the quarter ended June 30, 2025.
• All 32,220 shares are held with shared voting power and shared dispositive power among the reporting persons.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of beneficial ownership by an institutional investor. While not directly impacting financial performance, the establishment of a significant stake by Stonepine Capital could be viewed as a vote of confidence, hence a slightly positive sentiment.

Positives

• A significant institutional investor, Stonepine Capital, has taken a 5.6% stake in CNS Pharmaceuticals, Inc., which could be interpreted as a signal of confidence in the company's prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the issuer's future performance or operations.

Industry Context

The entry of a new institutional investor with a significant stake can sometimes bring increased market attention or potential for future engagement, which is a common dynamic in the biotechnology and pharmaceutical sectors where companies often rely on institutional funding and support for their development pipelines.

Stakeholder Impact

• Shareholders: Increased institutional ownership might be perceived positively, potentially enhancing market liquidity or signaling broader investor confidence in the company.

Key Dates

Recommendation

The Schedule 13G filing indicates a new 5.6% beneficial ownership by Stonepine Capital. While this signals institutional interest and potential confidence in CNS Pharmaceuticals, the filing itself does not provide financial performance data or strategic updates to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor for further developments or financial disclosures from the company.

Keywords

CNS Pharmaceuticals, Stonepine Capital, Schedule 13G, beneficial ownership, institutional investment, common stock, equity stake, pharmaceuticals